The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States.

JAMA. 1986 Jan 10;255(2):209-11. Unique Identifier : AIDSLINE MED/86089462
Hardy AM; Rauch K; Echenberg D; Morgan WM; Curran JW

Abstract: Acquired immunodeficiency syndrome (AIDS) is a serious, fatal disease affecting a relatively young population and has a great economic impact. Expenditures for hospitalization and economic losses from disability and premature death were estimated for the first 10,000 patients with AIDS reported in the United States. Extrapolation of data from surveys done in New York City, Philadelphia, and San Francisco suggests that these 10,000 patients with AIDS will require an estimated 1.6 million days in the hospital, resulting in over $1.4 billion in expenditures. Losses incurred for the 8,387 years of work that will be lost from disability and from the premature death of the 10,000 patients will be over $4.8 billion. The total economic burden of the AIDS epidemic will continue to rise as the number of diagnosed cases increases. These estimates reinforce the need for effective disease prevention strategies to reduce the number of cases.
Keywords: Acquired Immunodeficiency Syndrome/*ECONOMICS/EPIDEMIOLOGY Adolescence Adult Disability Evaluation Economic Value of Life Efficiency Female Hospitalization/ECONOMICS Human Male United States JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDeconomics/epidemiologyadolescenceadultdisabilityevaluationeconomicvalueoflifeefficiencyfemalehospitalization/economicshumanmaleunitedstatesjournalarticle
860430
M8640133

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .